Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07059832

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors

Application of 68Ga-NODAGA-SNA006 in Patients With Solid Tumor or Lymphoma

Status
Active Not Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
First Hospital of China Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.

Detailed description

The aim of this study was to explore the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in patients with solid tumors or lymphoma.

Conditions

Interventions

TypeNameDescription
DRUG68Ga-NODAGA-SNA00668Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.

Timeline

Start date
2024-04-01
Primary completion
2028-01-01
Completion
2028-04-01
First posted
2025-07-11
Last updated
2025-07-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07059832. Inclusion in this directory is not an endorsement.